STAT3 and neoplasm: ,41 Therefore, we hypothesized that CpG-Stat3 siRNA, at significantly lower and safer effective CpG concentrations, may enhance the antitumor efficacy of ICB by blocking STAT3 in the tumor-associated myeloid cells, thereby stimulating antigen presentation and activating CD4+ and CD8+ T cell-mediated antitumor immune responses.